New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it will hold a virtual Investor Day P ...